Mottaghi A, Bayat S, Taati K, Gholami M. Detection of Two Compound Heterozygous Variants in the CFTR Gene in a Patient with Cystic Fibrosis Using Whole-Exome Sequencing. , J Arak Uni Med Sci. 2026; 29 (4)
URL:
http://jams.arakmu.ac.ir/article-1-8271-en.html
1- Student Research Committee, Arak University of Medical Sciences, Arak, Iran
2- Department of Biochemistry and Genetics, School of Medicine, Arak University of Medical Sciences, Arak, Iran
3- Department of Biochemistry and Genetics, School of Medicine, Arak University of Medical Sciences, Arak, Iran , mtu.q220@gmail.com
Abstract: (109 Views)
Introduction: Cystic fibrosis is a fatal multisystemic disorder with an autosomal recessive inheritance pattern, predominantly affecting Caucasians. It results from mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The frequency of CFTR gene mutations varies depending on geographical location and ethnicity. The most common mutation in this gene, F508del, leads to reduced CFTR protein function and disease manifestation. This study aimed to perform a genetic analysis of a patient with cystic fibrosis using whole-exome sequencing (WES).
Methods: Peripheral blood samples were collected from a child with cystic fibrosis born to non-consanguineous parents. Genomic DNA was extracted and evaluated using WES. After data analysis, the potential pathogenic variants in the patient were confirmed and segregated using Sanger sequencing.
Ethical Considerations: This study was approved by the Ethics Committee of Arak University of Medical Sciences (IR.ARAKMU.REC.1404.140). All ethical principles were observed in accordance with the guidelines of the National Ethics Committee and COPE regulations.
Results: Two pathogenic compound heterozygous variants were identified in the patient for the first time in Iran, located in intron 2 (c.165-2A>G) and exon 15 (c.2537G>A) of the CFTR gene. Sanger sequencing confirmed that both parents of the affected individual were heterozygous carriers of the variants.
Conclusion: WES successfully identified the genetic cause in a patient suspected of having cystic fibrosis. High-throughput methods, such as WES, not only enable differential diagnosis but also contribute to preventive and advanced approaches, including gene therapy.
Type of Study:
Original Atricle |
Subject:
Basic Sciences Received: 2026/03/18 | Accepted: 2026/07/13